Evolus, Inc.
Evolus, Inc. (EOLS): 7 pipeline candidates · ~23 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
23.1 months
D/E -8.67 · 0% dilution
Lead: Approved
7 candidates
N/A
0 buys · 6 sells (180d)
A transparent, data-derived signal for Evolus, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$444.5M
Cash
$49.8M
Quarterly Burn
$10.0M
Runway
23.1 mo
Revenue
$73.1M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (7 candidates)
| Drug | Phase |
|---|---|
| evolysse | Preclinical |
| evolysse form | Approved |
| evolysse lips | Preclinical |
| evolysse sculpt | Preclinical |
| evolysse smooth | Approved |
| jeuveau | Approved |
| prabotulinumtoxina | — |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
145
Total value held
$151.5M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 4,940,816 | $20.3M |
| blackrock, inc. | 4,290,383 | $17.6M |
| braidwell lp | 3,105,209 | $12.8M |
| perceptive advisors llc | 2,573,724 | $10.6M |
| millennium management llc | 1,461,159 | $6.0M |
| armistice capital, llc | 1,396,000 | $5.7M |
| geode capital management, llc | 1,381,338 | $5.7M |
| state street corp | 1,320,790 | $5.4M |
| rice hall james & associates, llc | 1,254,819 | $5.2M |
| pinnacle associates ltd | 1,158,895 | $4.8M |
Showing top 10 of 145 institutional holders of Evolus, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Evolus, Inc.'s pipeline?
Evolus, Inc. (EOLS) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Evolus, Inc.'s lead drug candidate?
Evolus, Inc.'s most advanced tracked candidate is evolysse (Preclinical) for Improvement of moderate to severe nasolabial folds facial wrinkles, mid face volume, lip fullness and infraorbital hollow correction..
What is Evolus, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Evolus, Inc. has approximately 23.1 months of cash runway.
What is Evolus, Inc.'s market capitalization?
Evolus, Inc.'s market capitalization is approximately $444.5M.
Who is the CEO of Evolus, Inc.?
Mr. David Moatazedi is the chief executive officer of Evolus, Inc. (EOLS).
Get the full picture on Evolus, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.